Literature DB >> 21543708

How Brazil outpaced the United States when it came to AIDS: the politics of civic infiltration, reputation, and strategic internationalization.

Eduardo J Gómez1.   

Abstract

Using a temporal approach dividing the reform process into two periods, this article explains how both Brazil and the United States were slow to respond to AIDS. However, Brazil eventually outpaced the United States in its response due to international rather than democratic pressures. Since the early 1990s, Brazil's success has been attributed to "strategic internationalization": the concomitant acceptance and rejection of global pressure for institutional change and antiretroviral treatment, respectively. The formation of tripartite partnerships among donors, AIDS officials, and nongovernmental organizations has allowed Brazil to avoid foreign aid dependency, while generating ongoing incentives for influential AIDS officials to incessantly pressure Congress for additional funding. Given the heightened international media attention, concern about Brazil's reputation has contributed to a high level of political commitment. By contrast, the United States' more isolationist relationship with the international community, its focus on leading the global financing of AIDS efforts, and the absence of tripartite partnerships have prevented political leaders from adequately responding to the ongoing urban AIDS crisis. Thus, Brazil shows that strategically working with the international health community for domestic rather than international influence is vital for a sustained and effective response to AIDS.

Entities:  

Mesh:

Year:  2011        PMID: 21543708     DOI: 10.1215/03616878-1222739

Source DB:  PubMed          Journal:  J Health Polit Policy Law        ISSN: 0361-6878            Impact factor:   2.265


  1 in total

1.  The genesis of the AIDS policy and AIDS Space in Brazil (1981-1989).

Authors:  Sandra Garrido de Barros; Ligia Maria Vieira-da-Silva
Journal:  Rev Saude Publica       Date:  2016-07-21       Impact factor: 2.106

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.